Intended for healthcare professionals

  1. Research
  2. Incretin based drugs...
  3. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
CCBYNC Open access
Research

Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study

BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i581 (Published 17 February 2016) Cite this as: BMJ 2016;352:i581

Data supplement

Related articles

EditorialThe safety of incretin based drug treatments for type 2 diabetes

See more

Cited by...

  • Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
  • Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?
  • The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
  • Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial
  • iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
  • miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function
  • Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies
  • Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells
  • Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial
Back to top